依普利酮在国内多少钱一盒？

It was first approved for marketing in the United States in 2002, with the English name: Inspra. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Hypertension is the most common chronic disease and the main risk factor for cardiovascular and cerebrovascular diseases. Eplerenone, as a new generation of selective aldosterone receptor antagonist, provides a new method for the treatment of cardiovascular diseases.

Eplerenone selectively acts on aldosterone receptors and is highly selective on mineralocorticoid receptors, but has less effect on androgen and progesterone receptors. Its affinity for mineralocorticoids is 15 to 20 times that of spironolactone, while its affinity for androgen and progesterone receptors is 500 times smaller than that of spironolactone, so sex hormone-related adverse reactions are less likely to occur.

In the study, it was also found that the antihypertensive effect of eplerenone (Inspra) in patients with low-renin hypertension was significantly better than that of losartan. For patients with hypertension who are poorly controlled by ARB alone, adding eplerenone (50~100 mg·d) for 8 weeks can further enhance the effect of reducing DBP (diastolic blood pressure) and SBP (systolic blood pressure).

The effects of eplerenone are obvious to all. Many patients will inevitably ask: How much does a box of eplerenone cost in China?

(Inspra) has not yet been launched in China, so there is no domestic price. The time when eplerenone will be launched in my country is also unknown. Currently, more and more patients are choosing the Indian version of eplerenone, which is cheaper and almost as effective as the original drug. The Indian version of eplerenone (Inspra) comes in 50mg*100 tablets and costs around $500. If it is inconvenient for patients to go abroad to purchase, they can consult the medical companion travel service to learn how to purchase.

Recommended related hot articles: /newsDetail/72864.html